Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dr. Anna Suk-Fong Lok, Md to Joins Enochian Biosciences’ Hepatitis B Cure Scientific Advisory Board

08/23/2021 | 10:18am EDT

Enochian BioSciences, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the Scientific Advisory Board for a potential cure for Hepatitis B Virus (HBV), that causes liver disease in approximately 350 million people globally and 1 million deaths every year. Professor Lok is a leading clinical researcher. She is the Alice Lohrman Andrews Research Professor in Hepatology in the Department of Internal Medicine, at Michigan Medicine in Ann Arbor, Michigan and is the Director of Clinical Hepatology and Assistant Dean for Clinical Research in the University of Michigan Medical School. Dr. Lok's research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. She has published more than 550 papers on viral hepatitis and liver diseases, and has co-authored five editions of the American Association for the Study of Liver Diseases (AASLD) Guidelines on Hepatitis B. She is a former President of the AASLD. Dr. Lok was one of the top 1% of most cited scientists in the world for the decade 2002-2012.


© S&P Capital IQ 2021
All news about ENOCHIAN BIOSCIENCES, INC.
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
PU
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
AQ
10/12ENOCHIAN BIOSCIENCES : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C..
PU
10/12ENOCHIAN BIOSCIENCES : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C..
AQ
09/28ENOCHIAN BIOSCIENCES : Sinks 17%, Trading Volume Doubles Daily Average
MT
09/27ENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
PU
09/27ENOCHIAN BIOSCIENCES : Says Pre-Investigational New Drug Process Completed for Proposed He..
MT
09/27ENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
AQ
09/27Enochian Biosciences, Inc. Announces Its Successful Completion of FDA Pre-IND for A Pot..
CI
09/24ENOCHIAN BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Res..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -8,77x
Yield 2021 -
Capitalization 451 M 451 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,5%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.192.88%451
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156